Phase II Study to evaluate efficacy and safety of Lenalidomide maintenance therapy for multiple myeloma patients under bortezomib treatment
Phase 2
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000013881
- Lead Sponsor
- ational Defense Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 29
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are pregnant or lactating. 2. Patients who had been determined ineligible for any reason by physician. 3. Patients who have not achieved PR with bortezomib therapy as initial treatment. 4. Patients who progressed in disease status less than PR after the initial response.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method best response rate
- Secondary Outcome Measures
Name Time Method